Shed presents weight care within a larger wellness catalogue that also includes hair and longevity products. The weight-loss offer advertises compounded semaglutide from $159 per month and a separate tirzepatide starting rate. Those are specific offers within the catalogue, not a universal price for every Shed service.
The homepage’s 120-day weight-loss guarantee makes its commercial proposition memorable. The accompanying terms qualification matters just as much. This review describes the offer without treating a guarantee as a trial result or promising that a particular reader will receive money back.
The advertised medicine determines the quote
The reviewed weight-care section names compounded semaglutide at an as-low-as $159 monthly rate and a separate compounded tirzepatide starting figure. A weight-loss heading can contain several treatments, so a quote needs to identify which preparation and commitment it actually covers.
The page also advertises other wellness products at other rates. Their ingredients, purposes and offers cannot be added to the GLP-1 package by proximity. The cost guide explains why a selected medicine and complete term matter more than the catalogue’s lowest figure.
The guarantee is conditional commercial language
Shed advertises loss of 5% within 120 days or money back, with terms and conditions explicitly applying. That is a conditional refund offer. It is not proof that every member achieves that change, nor evidence that this review tested the program.
The exact qualifying requirements, documentation and exclusions would determine a refund request. They should not be filled in from the headline alone. The renewal and refund guide separates an advertised promise from a specific contractual right and a completed refund. In particular, an outcome-linked guarantee deserves a different reading from a refund when the clinician does not approve treatment.
Large program totals do not predict a person
The homepage promotes total pounds lost and a large membership count. These are aggregate program claims, not a measured average for a defined person, medicine or duration. A large cumulative figure does not identify the denominator or supply an individual expectation.
The compounded-product identity also needs to remain explicit. FDA says compounded GLP-1 preparations do not undergo the agency’s premarket review as approved finished drugs. A branded trial percentage or familiar active name does not establish an equivalent outcome from every dispensed preparation.
The practical strength and the open question
Shed makes its major treatment category and conditional guarantee visible, alongside an online access model. The useful open question is the complete selected prescription and purchase agreement, including what renews and how the guarantee works. This review did not complete an intake, buy a product or assess eligibility.
The Enhance.MD review distinguishes an introductory rate from the ongoing amount. The Embody review follows another low starting offer. The treatment guide provides context for medicine identity without treating the lowest advertised price as a clinical ranking.
Compare another model
Brightmeds · Enhance.MD · SnagRx · BetterMe Rx
The invoice guide and product-status guide explain the distinctions behind these entries.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.